摘要
目的检测瘢痕癌中PI3K/AKT信号通路中PI3K,AKT及其下游靶基因Bcl-2的表达,分析该通路靶向治疗靶点及靶向治疗的可行性。方法研究对象为瘢痕癌组织,以正常皮肤表皮为对照。免疫组织化学(SP法)技术检测PI3K,AKT,Bcl-2蛋白的表达;原位杂交技术检测PI3K mRNA,AKT mRNA的表达。结合图像分析,分别计算被检组织中所检各项指标的平均光密度和阳性面积,所有数据运用SPSS16.0软件进行统计学分析。结果 PI3K蛋白及其mRNA在正常皮肤表皮呈阴性表达,在瘢痕癌组织中呈阳性表达。瘢痕癌组表达水平、表达强度与正常皮肤组比较,差异有统计学意义(P<0.01)。AKT蛋白及其mRNA在正常皮肤表皮呈阴性表达,在瘢痕癌组织呈强阳性表达。瘢痕癌组表达水平、表达强度与正常皮肤组比较,差异有统计学意义(P<0.01)。Bcl-2在正常皮肤表皮和瘢痕癌组织中均呈阴性表达。其表达水平、表达强度两组之间比较差异无统计学意义(P>0.05)。结论 PI3K,AKT可能是瘢痕癌的致癌位点,实施靶向治疗的可行性存在。Bcl-2可能具有致癌位点的多样性,是否是瘢痕癌的致癌位点有待进一步探讨。
Objective To analyze the feasibility of the potential therapeutic targets of PI3K/AKT pathway by detecting the expression of PI3K,AKT and Bcl-2. Methods Skin scar carcinoma tissue was studied compared to normal skin epidermis. The protein expression of PI3K,AKT and Bcl-2 was detected by the S-P immunohistochemistry. The mRNA expression of PI3K and AKT was detected by in situ hybridization. The analysis of image were combined,and calculated the optical density and positive area indicators seized in the inspection organization,and all data was statistically analyzed by SPSS （16.0） software. Results Neither protein nor mRNA of PI3K and AKT was expressed in normal skin epidermis,which turned positive expression in scar carcinoma, indicating significant difference compared to the normal skin group （P 〈 0.01 ）. Bcl-2 was neither expressed in scar carcinoma tissue nor normal skin epidermis （P 〉 0.05）. Conclusion PI3K and AKT might be the carcinogenic sites and the potential therapeutic targets for scar cancer. However, due to its unclear carcinogenicity, further indepth work is needed to evidence the possibility of Bcl-2 as a therapeutic target.
出处
《中国皮肤性病学杂志》
CAS
北大核心
2014年第12期1220-1223,共4页
The Chinese Journal of Dermatovenereology
基金
贵州省科技攻关项目(2010-3080)
遵义医学院自然科学类招标课题(F-552)
